Fig. 6.7.2. A patient receiving chemotherapy in the context of cancer management.

Fig. 6.7.2

A patient receiving chemotherapy in the context of cancer management. The currently available data suggest improved clinical management based on the power of circulating cell-free tumour DNA (ctDNA) analysis to detect and monitor minimal residual disease in patients with cancer.

6.7.2. iStockphoto.com/Willowpix.

From: 6.7, Circulating DNA and other biomarkers for early diagnosis

Cover of World Cancer Report
World Cancer Report: Cancer research for cancer prevention.
Wild CP, Weiderpass E, Stewart BW, editors.
© International Agency for Research on Cancer, 2020. For more information contact publications@iarc.who.int.

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 IGO licence (CC BY-NC-ND 3.0 IGO; https://creativecommons.org/licenses/by-nc-nd/3.0/igo/). Under the terms of this licence, you may copy and redistribute the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.